Impax Laboratories – the marketer of the generic version of the Adrenaclick epinephrine auto-injector – is being acquired by Amneal Pharmaceuticals in a transaction that is expected to close in the first half of 2018.
Impax acquired the rights to the auto-injector when it acquired Amedra Pharmaceuticals in March of 2015. Now, following other such consolidations, Impax itself will be merged in with Amneal to form the fifth largest generics business in the US. The combined company will retain the name Amneal Pharmaceuticals.
Last January, CVS announced it was partnering with Impax to offer the Adrenaclick generic at a price of $109.99 per two-pack, a significant discount from Mylan’s EpiPen price tag.
“We are excited to join with Impax to create one of the most dynamic companies in the pharmaceutical industry,” said Chintu Patel, Co-Chief Executive Officer and Co-Chairman of Amneal. “This combination will help us achieve our long-term goals of providing greater access to safe and affordable medicine for people around the world, while also positioning us for continued success.”
Users of the auto-injector should expect the manufacturer information included with the product to change once the acquisition closes.
Source: Amneal And Impax To Combine – Company Press Release
Errata: a previous version of this article mistakenly included a photo of Mylan’s generic version of EpiPen.
